129 related articles for article (PubMed ID: 33070660)
1. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
Kim GP; Surinach A; Corvino FA; Cockrum P; Belanger B; Abushahin L
Future Oncol; 2021 Feb; 17(6):675-688. PubMed ID: 33070660
[No Abstract] [Full Text] [Related]
2. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
3. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
[TBL] [Abstract][Full Text] [Related]
5. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
6. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
[TBL] [Abstract][Full Text] [Related]
7. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
[TBL] [Abstract][Full Text] [Related]
8. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
9. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
[TBL] [Abstract][Full Text] [Related]
10. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
[TBL] [Abstract][Full Text] [Related]
12. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
13. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Bockorny B; Macarulla T; Semenisty V; Borazanci E; Feliu J; Ponz-Sarvise M; Abad DG; Oberstein P; Alistar A; Muñoz A; Geva R; Guillén-Ponce C; Fernandez MS; Peled A; Chaney M; Gliko-Kabir I; Shemesh-Darvish L; Ickowicz D; Sorani E; Kadosh S; Vainstein-Haras A; Hidalgo M
Clin Cancer Res; 2021 Sep; 27(18):5020-5027. PubMed ID: 34253578
[TBL] [Abstract][Full Text] [Related]
14. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Kodama T; Imajima T; Shimokawa M; Otsuka T; Kawahira M; Nakazawa J; Hori T; Shibuki T; Arima S; Ido A; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Sakai K; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Shirakawa T; Mizuta T; Mitsugi K
Sci Rep; 2024 May; 14(1):12422. PubMed ID: 38816500
[TBL] [Abstract][Full Text] [Related]
15. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Salvia R; Malleo G; Maggino L; Milella M; Bassi C
Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
[No Abstract] [Full Text] [Related]
17. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
19. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
